Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV Vaccines
Positive Pre-Clinical Data Reported On Vaccine Designed To Combat HIV's Ability To Mutate
April 11th, 2001
Epimmune Inc. (EPMN) announced on April 2, 2001, positive pre-clinical data on its HIV vaccine that is designed to directly address the problem of viral mutation. At the Keystone Symposium titled "AIDS Vaccines in the New Millennium" company scientists reported that the vaccine stimulated multiple anti-HIV cytotoxic T-cell immune responses in animal models. Epimmune has begun manufacturing the vaccine for human testing and plans to initiate clinical trials late this year or early 2002 in both non-infected volunteers and in individuals infected with HIV. The current standard HIV therapy in the U.S. is a three-drug...
Source: Vaccine Weekly (2001-04-11)
|
